With close to US$ 50 million invested in the country since 2007, Kenya is the third largest recipient worldwide of UNITAID funding. That funding has provided, among other things, child-friendly medicines to more than half of Kenyan children living with AIDS (57%) and about 135 000 TB treatments to Kenyan patients, including children.
NEW YORK, Sept. 30 /PRNewswire/ -- The Prix Galien USA committee honored innovations that are saving lives last night during the Prix Galien Awards Gala. The Pro Bono Humanum Award, the Prix Galien USA 2010 and the Prix Galien International were presented and related accomplishments celebrated.
Among the key speakers were the Queen of Jordan, Foreign Ministers of Japan, France, Spain, Minister for Development Cooperation of Norway and Belgium, Philippe Douste-Blazy (Chair of UNITAID and UN Special Adviser on Innovative Financing for Development), the European Commissioner for Development, the OECD Secretary General.
Philippe Douste-Blazy expressed the need for a UN resolution on innovative financing for development, so as to rally higher political support and generate a step-change in thinking.
A common theme that emerged from presentations was the focus not just on innovative ways of raising additional funds but also on innovative spending. UNITAID, in particular, has a good track record in this as it seeks to shape the health commodities market for sustainable access in developing countries, and has created the first ever medicines patent pool.
Following on a proposal by the UN Secretary-General, the General Assembly will convene a summit on 20-22 September on the Millennium Development Goals (MDGs) with the primary objective to accelerate progress towards the MDGs by 2015.
The MDGs were originally adopted in 2000 and incorporate key goals and targets of the broader development agenda, agreed upon by world leaders and other stakeholders at different UN Summits and Conferences.
Three of the MDGs are health-related - Goal 4 (children's health), Goal 5 (women's health) and Goal 6 (halt AIDS, TB and other infectious diseases). UNITAID works to contribute to all three of these goals by providing quality treatment for HIV/AIDS, malaria and TB, with particular attention to women and children. In addition, UNITAID contributes to Goal 8 (global partnerships) by engaging the pharmaceutical industry to collaborate to increase access to medicines.
UNITAID also represents one of the first innovative financing mechanisms set up to help achieve the MDGs by providing additional funding for health and by spending those funds in innovative, cost-effective ways.
The Chair of UNITAID, Philippe Douste-Blazy, is also Special Adviser to the UN Secretary General on Innovative Financing for Development.
Geneva, 14 September 2010 A new study to be published today reveals that Indian generic manufacturers have supplied more than 80% of donor-funded AIDS medicines to developing countries in the last seven years. However, it warns that upcoming trade agreements India is currently negotiating may close the tap on affordable medicines for AIDS patients. The news coincides with a global funding crisis in the area of AIDS while at the same time new clinical evidence demonstrates that greater investments are needed to address the disease.
The UNITAID Executive Board adopted a resolution on December 15 2009 that gave the go ahead for the establishment of a legal entity to house the Medicines Patent Pool. UNITAID has committed to provide funds of up to US$ 4 million in 2010 for the start up, subject to the approval of the budget.
On 5 February 2010, the UNITAID Executive Board met again to discuss outstanding matters, including an analysis, carried out by the Secretariat, of the appropriate legal structure for the Pool and its relationship with UNITAID. The resolution following this meeting can be found here.
UNITAID is now working on the necessary legal documents and action steps for the establishment of the Medicines Patent Pool Foundation.
The UNITAID Medicines Patent Pool Initiative has been met with a great degree of interest at the International AIDS Conference this week.
The medicines patent pool will be managed by the Medicines Patent Pool Foundation (MPPF), which will soon open for business and will be in a position to begin formal negotiations with the patent holders. The Medicines Patent Pool Foundation will initially focus exclusively on antiretrovirals (ARVs).
Discussions with a number of key ARV patent holders over the past few months have been encouraging. Some patent holders have expressed considerable interest in the initiative, and have been commended for that, including in the recently published Access to Medicines Index. However, contrary to some of this weeks media reports, no licensing agreements have been reached with any patent holders; recent and current conversations with the patent holders have been preliminary to the Medicines Patent Pool Foundation becoming fully operational.
Globalizing Solidarity: The Case for Financial Levies
"Innovative financing mechanisms have demonstrated their potential for securing additional resources for distribution to low-income countries. The success of the air ticket solidarity levy, as well as the governing body of revenue (UNITAID, International Drug Purchase Facility) has shown it is possible to meet long-term needs through non-traditional financing mechanisms."